How to buy Foundayo tablets online in the UK

Foundayo is now authorised in the UK for weight management. It contains orforglipron, an oral GLP-1 receptor agonist taken once daily.

To order Foundayo through Chemist Click, complete our confidential online weight-loss consultation. Your medical information will be reviewed to determine whether treatment is clinically appropriate for you.

Foundayo is a prescription-only medicine and an order does not guarantee that a prescription will be issued.

The MHRA authorised orforglipron under the brand name Foundayo on 10 August 2026 for weight management and type 2 diabetes. For weight management, it is licensed alongside a reduced-calorie diet and increased physical activity for eligible adults.

Foundayo Tablet Prices

Name & Dosage	x30 Tablets
Foundayo Tablets 0.8mg	£84.99
Foundayo Tablets 2.5mg	£104.99
Foundayo Tablets 5.5mg	£124.99
Foundayo Tablets 9mg	£149.99
Foundayo Tablets 14.5mg	£169.99
Foundayo Tablets 17.2mg	£174.99

Foundayo tablets: quick facts

Brand Name	Foundayo
Active ingredient	Orforglipron
Medication Class	GLP-1 receptor agonist
Form	Film-coated tablet
How often is it taken?	Once daily
Starting dose	0.8 mg once daily
Maximum dose	17.2 mg once daily
Does it need to be taken on an empty stomach?	No
Food restrictions when taking it?	No
Water restrictions when taking it?	No
Average weight loss	Up to 11.1% at 72 weeks using the treatment-regimen estimate in ATTAIN-1
UK approved?	Yes – authorised by the MHRA on 10 August 2026
Prescription required?	Yes
Manufacturer	Eli Lilly
Needs refrigeration?	No special temperature storage conditions are required. Keep it in the original packaging to protect it from light.
Available strengths	0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg and 17.2 mg tablets.

About Foundayo Tablets

What is Foundayo? Who can take it? How does it work? What makes orforglipron different? Results How quickly does Foundayo work? Foundayo vs Wegovy tablets Foundayo vs Mounjaro

What is Foundayo?

Foundayo is a once-daily prescription weight-loss tablet containing orforglipron.

Orforglipron is an oral GLP-1 receptor agonist developed by Eli Lilly, the manufacturer of Mounjaro.

Unlike injectable GLP-1 medicines, Foundayo is swallowed as a tablet. Unlike oral semaglutide, it does not need to be taken on an empty stomach and there are no food or water restrictions when taking the dose.

Foundayo is used alongside a reduced-calorie diet and increased physical activity to help eligible adults lose weight and maintain weight loss.

It was authorised by the MHRA in the UK on 10 August 2026.

Who can take Foundayo for weight loss?

Foundayo is licensed for weight management in adults with an initial:

BMI of 30 kg/m² or above, or
BMI from 27 kg/m² to below 30 kg/m² with at least one weight-related health condition.

Examples of weight-related conditions listed in the UK product information include:

Prediabetes
Type 2 diabetes
High blood pressure
Dyslipidaemia
Obstructive sleep apnoea
Cardiovascular disease

Meeting the licensed BMI criteria does not automatically mean Foundayo is suitable for you. Your medical history, current medicines and other clinical factors must also be considered before treatment is prescribed.

How does Foundayo work?

Foundayo contains orforglipron, a non-peptide GLP-1 receptor agonist.

GLP-1 is involved in several processes that regulate appetite and blood glucose.

Orforglipron activates GLP-1 receptors and can:

Reduce appetite
Reduce food intake
Increase feelings of fullness
Delay stomach emptying
Support improved blood-glucose control
Help reduce body weight when combined with dietary and lifestyle changes

Its effect on appetite helps people consume fewer calories over time, supporting sustained weight loss.

What makes orforglipron different?

Unlike peptide GLP-1 medicines such as semaglutide, orforglipron is a small-molecule, non-peptide GLP-1 receptor agonist.

This allows it to be formulated as a conventional once-daily tablet without the strict fasting administration requirements associated with some oral GLP-1 medicines.

Foundayo weight loss results

How much weight can you lose with Foundayo?

In the ATTAIN-1 Phase 3 trial, people taking the highest equivalent Foundayo dose lost an average of approximately 11.1% of their starting body weight over 72 weeks using the treatment-regimen estimate.

The study included adults living with obesity, or overweight plus a weight-related health condition, who did not have type 2 diabetes.

Average weight loss at 72 weeks

Foundayo tablet dose	Average weight change
5.5 mg	-7.4%
9 mg	-8.3%
17.2 mg	-11.1%
Placebo	-2.1%

Participants also followed dietary and physical-activity recommendations.

At the highest dose, more than half of participants achieved weight loss of at least 10% in the treatment-regimen analysis.

Individual results vary and weight loss is not guaranteed.

Another way the ATTAIN-1 results were analysed

When researchers estimated the effect in participants assuming treatment was continued as intended, average weight loss at the highest equivalent dose reached approximately 12.4% at week 72, compared with 0.9% with placebo.

This is why different publications may report Foundayo/orforglipron weight-loss results of approximately 11–12%.

Further reading:
Foundayo results: how much weight can you lose with orforglipron?

How quickly does Foundayo work?

Foundayo starts activating GLP-1 receptors after treatment begins, but meaningful weight loss develops gradually.

You may notice changes in appetite before seeing a substantial change on the scales.

Weight loss generally continues over many months as the dose is gradually increased and treatment is combined with appropriate dietary and lifestyle changes.

The main Phase 3 weight-management trial assessed results over 72 weeks, so Foundayo should be viewed as a long-term weight-management treatment rather than a quick weight-loss solution.

Foundayo vs Wegovy tablets

Foundayo and Wegovy tablets are both once-daily GLP-1 medicines used for weight management, but they contain different active ingredients and are taken differently.

Feature	Foundayo	Wegovy tablets
Active ingredient	Orforglipron	Semaglutide
Medicine class	GLP-1 receptor agonist	GLP-1 receptor agonist
Form	Tablet	Tablet
Frequency	Once daily	Once daily
Injection required?	No	No
Empty stomach required?	No	Yes
Food restrictions around dose?	No	Yes
Water restrictions?	No specific restriction	Small amount of plain water
Waiting period before food?	No	At least 30 minutes
Maximum dose	17.2 mg daily	25 mg daily
Highest average trial weight loss	Around 11–12%	Around 14–17% depending on analysis
UK authorised	Yes	Yes

There has not been a direct head-to-head clinical trial demonstrating that one tablet is superior to the other.

Foundayo may be particularly convenient for people who do not want to follow the fasting and timing requirements associated with oral semaglutide.

Further reading:
Foundayo vs Wegovy tablets

Foundayo vs Mounjaro

Foundayo and Mounjaro are both manufactured by Eli Lilly, but they are different medicines.

Foundayo contains orforglipron and is taken as a tablet once daily.

Mounjaro contains tirzepatide and is administered as an injection once weekly.

Mounjaro activates both GIP and GLP-1 receptors, whereas Foundayo acts on the GLP-1 receptor.

Clinical trial results from separate studies suggest Mounjaro generally produces greater average weight loss than Foundayo, but the medicines have not been directly compared in a head-to-head weight-management trial.

For some people, the convenience of a daily tablet with no injection may make Foundayo an attractive alternative.

How to take Foundayo tablets

Take one Foundayo tablet once every day.

A major advantage of Foundayo is that there are no food or water restrictions around the dose.

It can be taken:

At any time of day
With or without food
Without needing to fast beforehand
Without needing to wait before eating afterwards

The tablet should be swallowed whole.

Do not break, crush or chew Foundayo tablets.

Step-by-step

Step	What to do
1	Take one Foundayo tablet once daily.
2	Take it at a convenient time of day.
3	It can be taken regardless of meals.
4	There are no specific water restrictions when taking it.
5	Swallow the tablet whole.
6	Do not crush, chew or break the tablet.
7	Do not take more than one tablet in a day.

What if I forget to take Foundayo?

If you miss a dose of Foundayo, take your next dose as soon as possible.

Do not take more than one Foundayo tablet in the same day to make up for a missed dose.

Foundayo dosage

Foundayo treatment starts at 0.8 mg once daily.

The dose is increased gradually to help your body adjust to treatment and reduce gastrointestinal side effects.

Treatment stage	Earliest time	Foundayo dose
Starting dose	Days 1–30	0.8 mg once daily
Dose 2	After at least 30 days	2.5 mg once daily
Dose 3	After at least another 30 days	5.5 mg once daily
Dose 4	After at least another 30 days	9 mg once daily
Dose 5	After at least another 30 days	14.5 mg once daily
Maximum dose	After at least another 30 days	17.2 mg once daily

You do not necessarily need to reach 17.2 mg.

Dose increases after 2.5 mg are based on your response to treatment and how well you tolerate the medicine.

Your prescriber may therefore recommend remaining on a lower dose for longer.

The maximum licensed dose is 17.2 mg once daily. More than one tablet should not be combined to obtain a higher dose.

Foundayo side effects

The most common side effects of Foundayo affect the digestive system.

These tend to occur more frequently when starting treatment or increasing the dose and often reduce as the body becomes accustomed to treatment.

Very common Foundayo side effects

These may affect more than 1 in 10 people:

Side effect	What may help
Nausea	Eat smaller meals, eat slowly and avoid rich or fatty foods.
Diarrhoea	Drink sufficient fluids and seek advice if severe or persistent.
Vomiting	Take regular small amounts of fluid and seek advice if unable to keep fluids down.
Constipation	Maintain fluid intake, fibre and regular movement where appropriate.
Indigestion	Smaller meals and avoiding trigger foods may help.
Abdominal pain	Seek urgent medical advice if pain is severe or persistent.

Hypoglycaemia can also be very common when Foundayo is used alongside basal insulin.

Common side effects

Common side effects include:

Headache
Dizziness
Increased heart rate
Low blood pressure
Abdominal bloating
Burping
Acid reflux
Flatulence
Gallstones
Hair loss
Fatigue

Low blood sugar can also occur when Foundayo is taken with certain diabetes medicines such as sulfonylureas.

Serious Foundayo side effects and when to seek help

Seek urgent medical advice if you experience:

Severe, persistent stomach pain

Severe abdominal pain, particularly if persistent or associated with vomiting, may be a symptom of acute pancreatitis.

Stop treatment and seek immediate medical assessment if pancreatitis is suspected. If pancreatitis is confirmed, Foundayo should not be restarted.

Persistent vomiting or diarrhoea

Vomiting and diarrhoea can cause significant dehydration.

Severe dehydration can affect kidney function, so seek medical advice if you cannot keep fluids down or develop signs of significant dehydration.

Symptoms of gallbladder problems

Seek medical advice for symptoms such as severe upper abdominal pain, particularly with fever, nausea, vomiting or jaundice.

Gallbladder disease has been reported with GLP-1 medicines including orforglipron.

Foundayo warnings

Tell your prescriber before taking Foundayo if you:

Have previously had pancreatitis
Have severe gastrointestinal disease or severe gastroparesis
Have diabetes and use insulin or a sulfonylurea
Have diabetic retinopathy
Have severe liver impairment
Have severe heart failure
Have a history of gallbladder disease
Are due to have an operation requiring general anaesthesia or deep sedation
Are pregnant, breastfeeding or planning pregnancy
Take prescription, over-the-counter or herbal medicines that may interact with orforglipron

Orforglipron has not been studied adequately in some of these patient groups and may require additional precautions or may not be appropriate.

Foundayo interactions

Foundayo can interact with some medicines.

It is therefore important to tell your prescriber everything you take, including prescription medicines, over-the-counter products and herbal remedies.

Important interactions include certain medicines that strongly affect the CYP3A4 pathway.

For example:

Clarithromycin
Ketoconazole
Itraconazole
Ritonavir
Carbamazepine
Phenytoin
Rifampicin
St John’s wort

Some combinations should be avoided, while others can affect the maximum dose of Foundayo that can safely be prescribed.

The maximum Foundayo dose is 9mg once daily when used with certain strong CYP3A4 inhibitors or OATP1B inhibitors. Strong CYP3A4 inducers should generally be avoided because they can substantially reduce orforglipron exposure and effectiveness.

Foundayo and the contraceptive pill

This is an important difference to be aware of when starting Foundayo.

Orforglipron may reduce the effectiveness of oral hormonal contraceptives.

If you use an oral contraceptive pill, you should either:

switch to a non-oral contraceptive method, or
use an additional barrier contraceptive method

for 30 days after starting Foundayo and for 30 days after every dose increase.

Discuss contraception with your prescriber or pharmacist before starting treatment.

Foundayo during pregnancy and breastfeeding

Foundayo must not be used during pregnancy.

If you become pregnant while taking Foundayo, stop treatment and speak to your healthcare professional.

If you are planning pregnancy, Foundayo should be stopped at least 3 weeks before trying to conceive.

Foundayo while breastfeeding

Foundayo should not be used while breastfeeding.

It is not known whether orforglipron passes into human breast milk, and a risk to a breastfed infant cannot be excluded.

Frequently Asked Questions

Yes. Foundayo was authorised by the MHRA in the UK on 10 August 2026.

The UK became the first European country to authorise orforglipron for weight management and type 2 diabetes. It is a prescription-only medicine.

Foundayo is the UK brand name for orforglipron, a once-daily oral GLP-1 receptor agonist.

It is licensed for weight management in eligible adults alongside a reduced-calorie diet and increased physical activity.

Yes. Orforglipron is the active ingredient in Foundayo.

Foundayo is the brand name under which Eli Lilly markets orforglipron tablets in the UK.

Yes, Foundayo can be prescribed online in the UK where an appropriate clinical assessment has confirmed that treatment is suitable.

At Chemist Click, complete our confidential weight-loss consultation. Your information will then be reviewed before any prescription is issued.

No. Foundayo is a prescription-only medicine in the UK.

You should not buy Foundayo or purported orforglipron products from websites offering them without an appropriate prescription.

Foundayo prices at Chemist Click start from £82.97 for 30 tablets, depending on your prescribed dose.

The price includes your clinical assessment, prescription where appropriate, pharmacy dispensing and ongoing pharmacist support.

People taking the highest equivalent Foundayo dose lost approximately 11.1% of their starting weight on average over 72 weeks in the ATTAIN-1 treatment-regimen analysis.

Results vary between individuals and depend on factors including dose, treatment adherence, diet, physical activity and tolerance of treatment.

The maximum licensed Foundayo dose is 17.2 mg once daily.

Treatment starts at 0.8 mg and is gradually increased based on response and tolerability.

Foundayo tablets are available in:

0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg and 17.2 mg.

Foundayo can be taken once daily at any time of day.

Unlike some oral GLP-1 medicines, you do not need to take Foundayo on an empty stomach.

Yes. Foundayo can be taken regardless of food.

There is no requirement to fast before or after taking the tablet.

Yes. Foundayo does not have the food and water restrictions associated with oral semaglutide.

It can be taken once daily without food or water restrictions.

No. Foundayo does not require refrigeration.

It should be stored in its original packaging to protect it from light.

Yes. Orforglipron, the active ingredient in Foundayo, is a GLP-1 receptor agonist.

It activates GLP-1 receptors involved in appetite, food intake and blood-glucose regulation.

No. Foundayo is a tablet taken by mouth once daily.

It provides a needle-free alternative to injectable GLP-1 weight-loss medicines for suitable patients.

No. Foundayo and Mounjaro are different medicines made by Eli Lilly.

Foundayo contains orforglipron and is a daily GLP-1 tablet. Mounjaro contains tirzepatide, acts on both GIP and GLP-1 receptors and is injected once weekly.

No. Foundayo contains orforglipron, whereas Wegovy contains semaglutide.

Both activate the GLP-1 receptor, but they are different medicines.

There is currently no direct head-to-head trial showing that Foundayo is better than Wegovy tablets or vice versa.

Foundayo has the advantage of being taken without fasting or food restrictions, while separate clinical trials have reported greater average weight loss with high-dose oral semaglutide.

Treatment choice should take account of effectiveness, medical history, side effects, dosing preferences and clinical suitability.

Clinical trials of Mounjaro have reported greater average weight loss than the Foundayo ATTAIN-1 trial, but these medicines have not been directly compared in the same weight-loss trial.

It is therefore not appropriate to conclude from separate studies alone that one medicine will work better for a particular individual.

The most common Foundayo side effects are gastrointestinal symptoms including nausea, diarrhoea, constipation, vomiting, indigestion and abdominal pain.

These effects are particularly common while the dose is being increased and generally decrease over time.

Yes. Foundayo may reduce the effectiveness of oral hormonal contraceptives.

Use a non-oral contraceptive or an additional barrier method for 30 days after starting Foundayo and for 30 days following each dose increase.

Switching may be possible, but there is not a simple milligram-for-milligram conversion between Mounjaro and Foundayo.

Your prescriber should determine an appropriate starting dose and timing based on your existing treatment, side effects, medical history and the reason for switching.

Do not switch between GLP-1 medicines without clinical advice.

It may be possible to switch from Wegovy to Foundayo following clinical assessment.

Semaglutide and orforglipron are different medicines and their doses are not equivalent, so your Foundayo dose must be determined by your prescriber.

You should not take Foundayo alongside another GLP-1 weight-loss medicine unless specifically instructed by an appropriate specialist.

Combining GLP-1 treatments may increase adverse effects and is not part of standard weight-management treatment.

Authored by

Abbas Kanani

Superintendent Pharmacist

Written by Chemist Click

First created 28th August 2026

Last reviewed 3rd September 2026

Foundayo Tablets UK Oral Orforglipron Weight Loss Pills